Cyclophosphamide in multiple sclerosis: Scientific rationale, history and novel treatment paradigms

Therapeutic Advances in Neurological Disorders

Volumn 2, Issue 6, 2009, Pages 357-368

  Awad, Amer ^a   Stue, Olaf ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

cyclophosphamide; Cytoxan; immunology; MS; multiple sclerosis; therapy; treatment

Indexed keywords

ACROLEIN; ALEMTUZUMAB; AZATHIOPRINE; BETA1A INTERFERON; CORTICOTROPIN; CYCLOPHOSPHAMIDE; GLATIRAMER; GONADORELIN; IMMUNOSUPPRESSIVE AGENT; INTERFERON BETA SERINE; MESNA; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; PREDNISONE; RITUXIMAB; TESTOSTERONE; TYSARABI; UNCLASSIFIED DRUG;

ALOPECIA; AMENORRHEA; AZOOSPERMIA; BLADDER CANCER; BLOOD BRAIN BARRIER; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BRAIN ATROPHY; BREAST CARCINOMA; BRONCHOPNEUMONIA; CANCER INCIDENCE; CANCER RISK; CENTRAL NERVOUS SYSTEM; CLINICAL PRACTICE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DISEASE COURSE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG PENETRATION; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENCEPHALITIS; GONADAL DISEASE; HEMORRHAGIC CYSTITIS; HUMAN; IMMUNOGLOBULIN DEFICIENCY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; LOW DRUG DOSE; LYMPHOID TISSUE; LYMPHOMA; MONOTHERAPY; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; MYCOSIS FUNGOIDES; MYELOABLATIVE CONDITIONING; MYELOOPTIC NEUROPATHY; NAUSEA AND VOMITING; NEOPLASM; NEPHRITIS; NEUROBLASTOMA; NONHUMAN; OFF LABEL DRUG USE; OLIGOSPERMIA; OSTEOPOROSIS; OVARY ADENOCARCINOMA; PLASMAPHERESIS; PRACTICE GUIDELINE; PREGNANT WOMAN; PRIORITY JOURNAL; RETINOBLASTOMA; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SPINAL CORD; TERATOGENICITY;

EID: 77953389931     PISSN: 17562856     EISSN: None     Source Type: Journal    
DOI: 10.1177/1756285609344375     Document Type: Review

References (75)

1. Balshov, K.E., Smith, D.R., Khoury, S.J., Hafler, D.A. and Weinrer, H.L. ( 1997) Increased interleukin-12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand. Proc Natl Acad Sci USA 94: 599-603.
2. Blake, D.A., Heller, R.H., Hsu, S.H. and Schacter, B.Z. ( 1976) Return of fertility in a patient with cyclophosphamide-induced azoospermia. Johns Hopkins Med J 139: 20-22.
3. Blumenfeld, Z. ( 2007) Gender difference: fertility preservation in young women but not in men exposed to gonadotoxic chemotherapy. Minerva Endocrinol 32: 23-34.
4. CAMMS223 Trial Investigators, Coles, A.J., Compston, D.A., Selmaj, K.W., Lake, S.L., Moran, S., Margolin, D.H. et al. (2008 ) Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 359: 1786-1801.
5. Canadian Cooperative Multiple Sclerosis Study Group. ( 1991) The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 337: 441-446.
6. Chet, J.T., Collins, D.L., Atkins, H.L., Freedman, M.S., Galal, A. and Arnold, D.L. ( 2006) Brain atrophy after immunoablation and stem cell transplant in multiple sclerosis. Neurology 66: 1935-1937.
7. Coles, A.J., Cox, A., Le Page, E., Jones, J., Trip, S.A., Deans, J. et al. (2006) The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 253: 98-108.
8. Comabella, M., Balashov, K., Hafler, D.A., Issazadeh, S., Smith, D., Weiner, H.L. et al. (1998) Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. J Clin Invest 102: 671-678.
9. Compendium of Pharmaceuticals and Specialties. ( 2006) ®Cytoxan: Canadian Pharmacists Association (Canada).
10. Cree, B. ( 2006) Emerging monoclonal antibody therapies for multiple sclerosis. Neurologist 12: 171-178.
11. Cross, A.H., Stark, J.L., Lauber, J., Ramsbottom, M.J. and Lyons, J.A. ( 2006) Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 180: 63-70.
12. Crowe, J.S., Hall, V.S., Smith, M.A., Cooper, H.J. and Tite, J.P. ( 1992) Humanized monoclonal antibody CAMPATH-1H: myeloma cell expression genomic constructs nucleotide sequence of cDNA constructs and comparison of effector mechanisms of myeloma and Chinese hamster ovary cell-derived material. Clin Exp Immunol 87: 105-110.
13. de Bittencourt, P.R. and Gomes-da-Silva, M.M. ( 2005) Multiple sclerosis: long-term remission after a high dose of cyclophosphamide. Acta Neurol Scand 111: 195-198.
14. de Ridder, D., van Poppel, H., Demonthy, L., D'hooghe, B., Gonsette, R., Carton, H. et al. (1998) Bladder cancer in patients with multiple sclerosis treated with cyclophosphamide. J Urol 159: 1881-1884.
15. Drachman, D.B., Jones, R.J. and Brodsky, R.A. ( 2003) Treatment of refractory myasthenia: ‘rebooting’ with high-dose cyclophosphamide. Ann Neurol 53: 29-34.
16. Drachman, D.B., Adams, R.N., Hu, R., Jones, R.J. and Brodsky, R.A. ( 2008) Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis. Ann N Y Acad Sci 1132: 305-314.
17. Fassas, A., Passweg, J.R., Anagnostopoulos, A., Kazis, A., Kozak, T., Havrdova, E. et al. (2002) Hematopoietic stem cell transplantation for multiple sclerosis: a retrospective multicenter study. J Neurol 249: 1088-1097.
18. Flynn, J.M. and Byrd, J.C. ( 2000) Campath-1H monoclonal antibody therapy. Curr Opin Oncol 12: 574-581.
19. Freedman, M.S., Atkins, H.L., Arnold, D.L. and Bar-Or, A. on behalf of the Canadian BMT group (2007) Immune ablation and autologous stem cell transplantation for aggressive multiple sclerosis: interim 5-year report. Mult Scler 13(Suppl 2): 22(abstr).
20. Gauthier, S.A. and Weiner, H.L. ( 2005) Cyclophosphamide therapy for MS. Int MS J. 12: 52-58.
21. Gladstone, D.E., Golightly, M.G. and Brannagan, IIIT.H. ( 2007) High dose cyclophosphamide preferentially targets naïve T (CD45/CD4/RA+) cells in CIDP and MS patients. J Neuroimmunol 190: 121-126.
22. Gladstone, D.E., Zamkoff, K.W., Krupp, L., Peyster, R., Sibony, P., Christodoulou, C. et al. (2006) Highdose cyclophosphamide for moderate to severe refractory multiple sclerosis. Arch Neurol 63: 1388-1393.
23. Gobbini, M.I., Smith, M.E., Richert, N.D., Frank, J.A. and McFarland, H.F. ( 1999) Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis. J Neuroimmunol 99: 142-149.
24. Hartung, H.P., Gonsette, R., Konig, N., Kwiecinski, H., Guseo, A., Morrissey, S.P. et al. (2002) Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multi-centre trial. Lancet 360: 2018-2025.
25. Hauser, S.L., Dawson, D.M., Lehrich, J.R., Beal, M.F., Kevy, S.V., Propper, R.D. et al. (1983) Intensive immunesuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 308: 173-180.
26. Hemmer, B. and Stuve, O. ( 2007) Revised criteria for neuromyelitis optica - a new diagnostic standard? Nat Clin Pract Neurol 3: 132-133.
27. Hohol, M.J., Olek, M.J., Orav, E.J., Stazzone, L., Hafler, D.A., Khoury, S.J. et al. (1999) Treatment of progressive multiple sclerosis with pulse cyclophosphamide/methylprednisolone: response to therapy is linked to the duration of progressive disease. Mult Scler 5: 403-409.
28. Hommes, O.R., Prick, J.J. and Lamers, K.J. ( 1975) Treatment of chronic progressive form of multiple sclerosis with a combination of cyclophosphamide and prednisone. Clin Neurol Neurosurg 78: 59-72.
29. Inglese, M., Mancardi, G.L., Pagani, E., Rocca, M.A., Murialdo, A., Saccardi, R. et al. (2004) Brain tissue loss occurs after suppression of enhancement in patients with multiple sclerosis treated with autologous haematopoietic stem cell transplantation. J Neurol Neurosurg Psychiatry 75: 643-644.
30. Khan, O.A., Zavartau-Hind, M., Caon, C., Din, M.U., Cochran, M., Lisak, D. et al. (2001) Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy. Mult Scler 7: 185-188.
31. Kanter, I.C., Huttner, H.B., Staykov, D., Biermann, T., Struffert, T., Kerling, F. et al. (2008) Cyclophosphamide for anti-GAD antibody-positive refractory status epilepticus. Epilepsia 49: 914-920.
32. Karni, A., Balashov, K., Hancock, W.W., Bharanidharan, P., Abraham, M., Kohoury, S.J. et al. (2004) Cyclophosphamide modulates CD4+ T cells into a T helper type 2 phenotype and reverses increased IFN-γ production of CD8+ T cells in secondary progressive multiple sclerosis. J Neuroimmunol 146: 189-198.
33. Kim, Y.H., Choi, B.K., Oh, H.S., Kang, W.J., Mittler, R.S. and Kwon, B.S. (2009) Mechanisms involved in synergistic anti-cancer effects of anti 4-1-BB and cyclophosphamide therapy. Mol Cancer Ther 8: 469-478.
34. Kovarsky, J. ( 1983) Clinical pharmacology and toxicology of Cyclophosphamide: emphasis on use in rheumatic diseases. Semin Arthritis Rheum 12: 359-372.
35. Krishnan, C., Kaplin, A.I., Brodsky, R.A., Drachman, D.B., Jones, R.J., Pham, D.L. et al. (2008) Reduction of disease activity and disability with highdose cyclophosphamide in patients with aggressive multiple sclerosis. Arch Neurol 65: 1044-1051.
36. Kurtzke, J.F. ( 1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33: 1444-1452.
37. La Mantia, L., Eoli, M., Salmaggi, A., Torri, V. and Milanese, C. ( 1998) Cyclophosphamide in chronic progressive multiple sclerosis: a comparative study. Ital J Neurol Sci 19: 32-36.
38. Lebrun, C., Debouverie, M., Vermersch, P., Clavelou, P., Rumbach, L., de Seze, J. et al. (2008) Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis. Mult Scler 14: 399-405.
39. Likosky, W.H., Fireman, B., Elmore, R., Eno, G., Gale, K., Goode, G.B. et al. (1991) Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study. J Neurol Neurosurg Psychiatry 54: 1055-1060.
40. Lublin, F.D. and Reingold, S.C. ( 1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46: 907-911.
41. Makhani, M.P., Gorman, H.M., Branson, L., Stazzone, B.L., Banwell, T. and Chitnis. (2009) Cyclophosphamide therapy in pediatric multiple sclerosis. Neurology 72: 2076-2082.
42. Masala, A., Faedda, R., Alagna, S., Satta, A., Chiarelli, G., Rovasio, P.P. et al. (1997) Use of testosterone to prevent cyclophosphamide-induced azoospermia. Ann Intern Med 126: 292-295.
43. Meirow, D., Epstein, M., Lewis, H., Nugent, D. and Gosden, R.G. ( 2001) Administration of cyclophosphamide at different stages of follicular maturation in mice: effects on reproductive performance and fetal malformations. Hum Reprod 16: 632-637.
44. Moore, M.J. ( 1991) Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 20: 194-208.
45. Oger, J. ( 2007) Immunosuppression: promises and failures. J Neurol Sci 259: 74-78.
46. ONS Clinical Practice Committee. (1999) Cancer Chemotherapy Guidelines and Recommendations for Practice. Pittsburgh, PA: ONS, pp. 32-41.
47. Patti, F., Reggio, E., Palermo, F., Fiorilla, T., Politi, G., Nicoletti, A. et al. (2004) Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta. J Neurol 251: 1502-1506.
48. Perini, P., Calabrese, M., Rinaldi, L. and Gallo, P. ( 2007) The safety profile of cyclophosphamide in multiple sclerosis therapy. Expert Opin Drug Saf 6: 183-190.
49. Perini, P. and Gallo, P. ( 2003) Cyclophosphamide is effective in rapidly deteriorating secondary progressive multiple sclerosis. J Neurol 250: 834-838.
50. Polman, C.H., Reingold, S.C., Edan, G., Filippi, M., Hartung, H.P., Kappos, L. et al. (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the ‘McDonald Criteria’. Ann Neurol 58: 840-846.
51. Portaccio, E., Siracusa, G., Piacentini, S., Sorbi, S. and Amato, M.P. ( 2003) Safety and tolerability of cyclophosphamide ‘pulses’ in multiple sclerosis: a prospective study in a clinical cohort. Mult Scler 9: 446-450.
52. Poser, C.M., Party, D.W., Scheinberg, L., McDonald, W.I., Davis, F.A., Ebers, G.C. et al. (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13: 227-231.
53. Prineas, J.W. ( 1979) Multiple sclerosis: presence of lymphatic capillaries and lymphoid tissue in the brain and spinal cord. Science 203: 1123-1125.
54. Prineas, J.W. and Wright, R.G. ( 1978) Macrophages, lymphocytes, and plasma cells in the perivascular compartment in chronic multiple sclerosis. Lab Invest 38: 409-421.
55. Radis, C.D., Kahl, L.E., Baker, G.L., Wasko, M.C., Cash, J.M., Gallatin, A. et al. (1995) Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year follow up study. Arthritis Rheum 38: 1120-1127.
56. Roccatagliata, L., Rocca, M.A., Valsasina, P., Bonzano, L., Sormani, M., Saccardi, R. et al. (2007) The long-term effect of AHSCT on MRI measures of MS evolution: a five year follow-up study. Mult Scler 13: 1068-1070.
57. Saccardi, R., Kozak, T., Bocelli-Tyndall, C., Fassas, A., Kazis, A., Havrdova, E. et al. (2006) Autologous stem cell transplantation for progressive multiple sclerosis: Update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. Mult Scler 12: 814-823.
58. Schwartzman, R.J., Simpkins, N., Alexander, G.M., Reichenberger, E., Ward, K., Lindenberg, N. et al. (2009) High-dose cyclophosphamide in the treatment of multiple sclerosis. CNS Neurosci Ther 15: 118-127.
59. Smith, D.R. ( 2005) Cyclophosphamide therapy for multiple sclerosis. In: Olek, M.J. (ed.). Multiple Sclerosis Humana Press: New York, pp. 171-191.
60. Smith, D.R., Balashov, K.E., Hafler, D.A., Khoury, S.J. and Weiner, H.L. ( 1997) Immune deviation following pulse cyclophosphamide / methylprednisolone treatment of multiple sclerosis: increased interleukin-4 production and associated eosinophilia. Ann Neurol 42: 313-318.
61. Smith, D.R., Weinstock-Guttman, B., Cohen, J.A., Wei, X., Gutmann, C., Bakshi, R. et al. (2005) A randomized blinded trial of combination therapy with cyclophosphamide in patients with active multiple sclerosis on interferon beta. Mult Scler 11: 573-582.
62. Steinman, L. ( 2001) Multiple sclerosis: a two-stage disease. Nat Immunol 2: 762-764.
63. Stuve, O., Cravens, P.D., Frohman, E.M., Phillips, J.T., Remington, G.M., von Geldern, G. et al. (2009) Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology 72: 396-401.
64. Stuve, O., Marra, C.M., Jerome, K.R., Cook, L., Cravens, P.D., Cepok, S. et al. (2006) Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 59: 743-747.
65. Takamoto, S., Sakura, N., Namera, A. and Yashiki, M. ( 2004) Monitoring of urinary acrolein concentration in patients receiving cyclophosphamide and ifosphamide. J Chromatogr B Analyt Technol Biomed Life Sci 806: 59-63.
66. Takashima, H., Smith, D.R., Fukaura, H., Khoury, S.J., Hafler, D.A. and Weiner, H.L. ( 1998) Pulse cyclophosphamide plus methylprednisolone induces myelin-antigen-specific IL-4 secreting T cells in multiple sclerosis patients. Clin Immunol Immunopathol 88: 28-34.
67. Talar-Williams, C., Hijazi, Y.M., Walther, M.M., Linehan, W.M., Hallahan, C.W., Lubensky, I. et al. (1996) Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 124: 477-484.
68. Tamir, S. and Tannenbaum, S.R. ( 1996) The role of nitric oxide (NO.) in the carcinogenic process. Biochim Biophys Acta 1288: F31-F36
69. Ujházy, E., Balonová, T., Durisová, M., Gajdosík, A., Jansák, J. and Molnárová, A. ( 1993) Teratogenicity of cyclophosphamide in New Zealand white rabbits. Neoplasma 40: 45-49.
70. Weiner, H.L., Mackin, G.A., Orav, E.J., Hafler, D.A., Dawson, D.M., LaPierre, Y. et al. (1993) Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 43: 910-918.
71. Weinstock-Guttman, B. ( 1997) Treatment of fulminant multiple sclerosis with intravenous cyclophosphamide. The Neurologist 3: 178-185.
72. Wetzels, J.F.M. ( 2004) Cyclophosphamide-induced gonadal toxicity: a treatment dilemma in patients with lupus nephritis. Neth J Med 62: 347-352.
73. Zephir, H., de Seze, J., Duhamel, A., Debouverie, M., Hautecoeur, P., Lebrun, C. et al. (2004) Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients. J Neurol Sci 218: 73-77.
74. Zipoli, V., Portaccio, E., Hakiki, B., Siracusa, G., Sorbi, S. and Amato, M.P. ( 2008) Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: An open-label comparative study of efficacy and safety. J Neurol Sci 266: 25-30.
75. Zivadinov, R., Reder, A.T., Fillippi, M., Minagar, A., Stüve, O., Lassmann, H. et al. (2008) Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology 71: 136-144.